Frank R Lichtenberg
Biographic Data
| ID | 1730843 |
|---|---|
| NAME | Frank R Lichtenberg |
| GIVEN NAMES | Frank R |
| FAMILY NAME | Lichtenberg |
| SIGNATURE | LICHTENBERG F R |
| AFFILIATIONS | Columbia University |
| ORCID | 0000-0002-5113-9681 |
| VERIFIED | Yes |
| TOTAL WORKS | 18 |
| TOTAL CITATIONS | 3 |
| WORKS AS AUTHOR | 18 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 1984 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 1 |
The impact of biomedical innovation on US mortality, 1999–2019
We investigate whether the diseases for which there was more biomedical innovation had larger 1999–2019 reductions in premature mortality. Biomedical innovation related to a disease is measured by the change in the mean vintage of descriptors of PubMed articles about the disease. We analyze data on 286 million descriptors of 27 million articles about over 800 diseases. Premature mortality from a disease is significantly inversely related to the l…
The impact of biomedical innovation on cancer mortality in 37 countries, 2003–2017
Number of drugs provided by the Pharmaceutical Benefits Scheme and mortality and hospital utilization in Australia, 2002–2019
We analyze the relationship between long-run changes in the drugs provided by the Pharmaceutical Benefits Scheme (PBS) and mortality and hospital utilization in Australia, by analyzing the correlation across diseases between the change in the number of drugs used to treat the disease provided and the subsequent change in mortality or hospital utilization from that disease. Our estimates indicate that diseases for which there were larger increases…
The effect of pharmaceutical innovation on longevity
This study examines the impact that pharmaceutical innovation, which accounts for most private biomedical research expenditure, has had on longevity. We perform two types of two-way fixed-effects analyses, which control for the effects of many potentially confounding variables. First, we analyze long-run (2006-2018) changes in longevity associated with different diseases in a single country: the U.S. Then, we analyze relative longevity levels ass…
The impact of pharmaceutical innovation on the burden of disease in Canada, 2000–2016
We perform an econometric assessment of the role that pharmaceutical innovation-the introduction and use of new drugs-has played in reducing the burden of disease in Canada, by investigating whether diseases for which more new drugs were launched had larger subsequent reductions in disease burden. Since utilization of a drug reaches a peak about 12-14 years after it was launched, we allow for considerable lags in the relationship between new drug…
The impact of recent chemotherapy innovation on the longevity of myeloma patients
The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009
The impact of therapeutic procedure innovation on hospital patient longevity
Pharmaceutical innovation and mortality in the United States, 1960–2000. A commentary on Schnittker and Karandinos
Pharmaceutical Price Discrimination and Social Welfare
Price discrimination is an extremely common type of pricing strategy engaged in by virtually every business with some discretionary pricing power. The issue of whether price discrimination reduces or increases social welfare has been considered by economists since at least 1920. At that time, it was demonstrated that, under certain (restrictive) conditions, price discrimination will reduce social welfare. Subsequent research has shown that price …
The effect of new drug approvals on HIV mortality in the US, 1987–1998
Does Foreign Direct Investment Transfer Technology Across Borders
Previous studies have found that importing goods from R&D-intensive countries raises a country's productivity. In this paper, we investigate econometrically whether foreign direct investment (FDI) also transfers technology across borders. The data indicates that FDI transfers technology, but only in one direction: a country's productivity is increased if it invests in R&D-intensive foreign countries—particularly in recent years—but not if foreign…
Testing the Convergence Hypothesis
The authors show that, contrary to the beliefs of some previous analysts of international economic growth, the hypotheses of convergence and of mean-reversion are not equivalent. Under some assumptions, the rate of convergence is independent of the degree of mean-reversion; under other assumptions, mean-reversion is a necessary, but not a sufficient, condition for convergence. The authors show the relationship between the convergence test and the…
Errors of Measurement in Output Deflators
In this paper we investigate the incidence of measurement errors in two independent estimates of long-term price change, within the framework of "multiple indicators" models of price measurement. We develop estimates of the measurement-error variances associated with both the Producer Price Index (PPI) and the Census Unit Value Relative (UVR) . Our estimates provide support for the generally accepted view that the PPI is a far more reliable indic…
The Impact of the Strategic Defense Initiative on US Civilian R&D Investment and Industrial Competitiveness
At a time when US industrial competitiveness was at its lowest point in the modern era, the Reagan Administration requested unprecedented sums for research and development of the Strategic Defense Initiative (SDI). If funded at the levels requested, SDI would further weaken the US competitive position by substantially reducing the amount of civilian R&D investment. Past military R&D has made a negligible contribution to US economic performance, a…
Estimation of the Internal Adjustment Costs Model Using Longitudinal Establishment Data
This paper develops estimates of the internal costs (measured in terms of foregone current output) associated with the introduction of new plant and equipment into manufacturing establishments, using the Census Bureau's Longitudinal Establishment Data file, a very large and rich source of production and investment data. Our estimates provide strong support for the internal-adjustment-costs hypothesis; they indicate that one-dollar increases in ex…
The Comparative Advantage of Educated Workers in Implementing New Technology
The authors estimate labor dem and equations derived from a (restricted variable) cost function in which "experience" on a technology (proxied by the mean age of the capital stock) enters "non-neutrally." The specification of the underlying cost function isbased on the hypothesis that highly educated workers have a comparative advantage with re spect to the adjustment to, and implementation of, new technologies. The empiric al results are consist…
Interindustry Technology Flows and Productivity Growth
5. This finding may reflect both the fact that, relatively speaking, manufacturing industries do not "import" much R&D (though they "export" a lot to non-manufacturing industries) and that at the more disaggregated levels used by us Scherer's estimates are based on smaller samples and may be subject to more significant errors in variables problems.On the first point, see Scherer (1982b, p. 233)
The Impact of the Strategic Defense Initiative on US Civilian R&D Investment and Industrial Competitiveness
At a time when US industrial competitiveness was at its lowest point in the modern era, the Reagan Administration requested unprecedented sums for research and development of the Strategic Defense Initiative (SDI). If funded at the levels requested, SDI would further weaken the US competitive position by substantially reducing the amount of civilian R&D investment. Past military R&D has made a negligible contribution to US economic performance, a…
The impact of therapeutic procedure innovation on hospital patient longevity
Interindustry Technology Flows and Productivity Growth
5. This finding may reflect both the fact that, relatively speaking, manufacturing industries do not "import" much R&D (though they "export" a lot to non-manufacturing industries) and that at the more disaggregated levels used by us Scherer's estimates are based on smaller samples and may be subject to more significant errors in variables problems.On the first point, see Scherer (1982b, p. 233)
The Comparative Advantage of Educated Workers in Implementing New Technology
The authors estimate labor dem and equations derived from a (restricted variable) cost function in which "experience" on a technology (proxied by the mean age of the capital stock) enters "non-neutrally." The specification of the underlying cost function isbased on the hypothesis that highly educated workers have a comparative advantage with re spect to the adjustment to, and implementation of, new technologies. The empiric al results are consist…
Estimation of the Internal Adjustment Costs Model Using Longitudinal Establishment Data
This paper develops estimates of the internal costs (measured in terms of foregone current output) associated with the introduction of new plant and equipment into manufacturing establishments, using the Census Bureau's Longitudinal Establishment Data file, a very large and rich source of production and investment data. Our estimates provide strong support for the internal-adjustment-costs hypothesis; they indicate that one-dollar increases in ex…
Errors of Measurement in Output Deflators
In this paper we investigate the incidence of measurement errors in two independent estimates of long-term price change, within the framework of "multiple indicators" models of price measurement. We develop estimates of the measurement-error variances associated with both the Producer Price Index (PPI) and the Census Unit Value Relative (UVR) . Our estimates provide support for the generally accepted view that the PPI is a far more reliable indic…
The Impact of the Strategic Defense Initiative on US Civilian R&D Investment and Industrial Competitiveness
At a time when US industrial competitiveness was at its lowest point in the modern era, the Reagan Administration requested unprecedented sums for research and development of the Strategic Defense Initiative (SDI). If funded at the levels requested, SDI would further weaken the US competitive position by substantially reducing the amount of civilian R&D investment. Past military R&D has made a negligible contribution to US economic performance, a…
Testing the Convergence Hypothesis
The authors show that, contrary to the beliefs of some previous analysts of international economic growth, the hypotheses of convergence and of mean-reversion are not equivalent. Under some assumptions, the rate of convergence is independent of the degree of mean-reversion; under other assumptions, mean-reversion is a necessary, but not a sufficient, condition for convergence. The authors show the relationship between the convergence test and the…
Does Foreign Direct Investment Transfer Technology Across Borders
Previous studies have found that importing goods from R&D-intensive countries raises a country's productivity. In this paper, we investigate econometrically whether foreign direct investment (FDI) also transfers technology across borders. The data indicates that FDI transfers technology, but only in one direction: a country's productivity is increased if it invests in R&D-intensive foreign countries—particularly in recent years—but not if foreign…
The effect of new drug approvals on HIV mortality in the US, 1987–1998
Pharmaceutical innovation and mortality in the United States, 1960–2000. A commentary on Schnittker and Karandinos
Pharmaceutical Price Discrimination and Social Welfare
Price discrimination is an extremely common type of pricing strategy engaged in by virtually every business with some discretionary pricing power. The issue of whether price discrimination reduces or increases social welfare has been considered by economists since at least 1920. At that time, it was demonstrated that, under certain (restrictive) conditions, price discrimination will reduce social welfare. Subsequent research has shown that price …
The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009
The impact of therapeutic procedure innovation on hospital patient longevity
The impact of recent chemotherapy innovation on the longevity of myeloma patients
The impact of pharmaceutical innovation on the burden of disease in Canada, 2000–2016
We perform an econometric assessment of the role that pharmaceutical innovation-the introduction and use of new drugs-has played in reducing the burden of disease in Canada, by investigating whether diseases for which more new drugs were launched had larger subsequent reductions in disease burden. Since utilization of a drug reaches a peak about 12-14 years after it was launched, we allow for considerable lags in the relationship between new drug…
The effect of pharmaceutical innovation on longevity
This study examines the impact that pharmaceutical innovation, which accounts for most private biomedical research expenditure, has had on longevity. We perform two types of two-way fixed-effects analyses, which control for the effects of many potentially confounding variables. First, we analyze long-run (2006-2018) changes in longevity associated with different diseases in a single country: the U.S. Then, we analyze relative longevity levels ass…
Number of drugs provided by the Pharmaceutical Benefits Scheme and mortality and hospital utilization in Australia, 2002–2019
We analyze the relationship between long-run changes in the drugs provided by the Pharmaceutical Benefits Scheme (PBS) and mortality and hospital utilization in Australia, by analyzing the correlation across diseases between the change in the number of drugs used to treat the disease provided and the subsequent change in mortality or hospital utilization from that disease. Our estimates indicate that diseases for which there were larger increases…
The impact of biomedical innovation on cancer mortality in 37 countries, 2003–2017
The impact of biomedical innovation on US mortality, 1999–2019
We investigate whether the diseases for which there was more biomedical innovation had larger 1999–2019 reductions in premature mortality. Biomedical innovation related to a disease is measured by the change in the mean vintage of descriptors of PubMed articles about the disease. We analyze data on 286 million descriptors of 27 million articles about over 800 diseases. Premature mortality from a disease is significantly inversely related to the l…
Economics (10 works) · Medicine (8 works) · Pharmaceutical Economics and Policy (8 works) · Econometrics (5 works) · Economic Growth and Productivity (5 works) · Gerontology (5 works) · Global Health Care Issues (4 works) · Health Systems, Economic Evaluations, Quality of Life (4 works) · Longevity (4 works) · Mathematics (4 works)